The antimalarial drug mefloquine could help treat genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy and some cancers.

Scientists at St. Jude Children’s Research Hospital and the Medical College of Wisconsin have discovered how chemokines and G protein-coupled receptors selectively bind each other to control how cells move.

New research from Memorial Sloan Kettering Cancer Center (MSK) identifies a rare cell population responsible for AML persistence and resistance to therapy; sheds new light on early brain development; and investigates how other health conditions can increase cancer risk in midlife. MSK clinical trials also supported the recent approval of the targeted drug larotrectinib by the FDA.

"This study significantly advances our understanding about how blood cancers develop and progress, especially in older adults," says corresponding author Dr. Dan Starczynowski, Cincinnati Children's.

For many cancer patients, side effects from radiation can be debilitating. But a new way of delivering radiation treatment has proven effective at eliminating a hard-to-treat cancer with the only side effect being light skin discoloration, even nine months after treatment. This new treatment, step-and-shoot proton arc therapy, is the first to be used by physicians and scientists to treat a patient at Corewell Health William Beaumont University Hospital in Royal Oak, Michigan.

In a new report released today, American Cancer Society (ACS) researchers discovered mixed progress in major cancer risk factors, preventive behaviors, and screenings in the post-COVID-19 pandemic period among adults in the United States. Smoking rates continued a long-term declining trend during the COVID-19 pandemic, but 27 million adults still smoked in 2023. Breast and colorectal cancer (CRC) screening rebounded after decreasing or stalling during the pandemic. However, past-year cervical cancer screening remained lower than pre-pandemic levels, continuing a disappointing pattern in up-to-date screening in the past two decades.